These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 23530581

  • 1. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.
    Daniels V, Wood M, Leclercq K, Kaminski RM, Gillard M.
    Br J Pharmacol; 2013 Jul; 169(5):1091-101. PubMed ID: 23530581
    [Abstract] [Full Text] [Related]

  • 2. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD, Gillard M.
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor.
    Wood M, Daniels V, Provins L, Wolff C, Kaminski RM, Gillard M.
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
    Gillard M, Fuks B, Leclercq K, Matagne A.
    Eur J Pharmacol; 2011 Aug 16; 664(1-3):36-44. PubMed ID: 21575627
    [Abstract] [Full Text] [Related]

  • 6. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD, Sands ZA, Vandenplas C, Gillard M.
    Epilepsia; 2018 Sep 16; 59(9):e147-e151. PubMed ID: 30144048
    [Abstract] [Full Text] [Related]

  • 7. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B.
    Proc Natl Acad Sci U S A; 2004 Jun 29; 101(26):9861-6. PubMed ID: 15210974
    [Abstract] [Full Text] [Related]

  • 8. Solubilization and immunopurification of rat brain synaptic vesicle protein 2A with maintained binding properties.
    Lambeng N, Grossmann M, Chatelain P, Fuks B.
    Neurosci Lett; 2006 May 01; 398(1-2):107-12. PubMed ID: 16434140
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Visualization of SV2A conformations in situ by the use of Protein Tomography.
    Lynch BA, Matagne A, Brännström A, von Euler A, Jansson M, Hauzenberger E, Söderhäll JA.
    Biochem Biophys Res Commun; 2008 Oct 31; 375(4):491-5. PubMed ID: 18692481
    [Abstract] [Full Text] [Related]

  • 11. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B.
    Epilepsia; 2016 Apr 31; 57(4):538-48. PubMed ID: 26920914
    [Abstract] [Full Text] [Related]

  • 12. Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis.
    Lee J, Daniels V, Sands ZA, Lebon F, Shi J, Biggin PC.
    PLoS One; 2015 Apr 31; 10(2):e0116589. PubMed ID: 25692762
    [Abstract] [Full Text] [Related]

  • 13. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H.
    Br J Pharmacol; 2008 Aug 31; 154(8):1662-71. PubMed ID: 18500360
    [Abstract] [Full Text] [Related]

  • 14. Interaction of Approved Drugs with Synaptic Vesicle Protein 2A.
    Danish A, Namasivayam V, Schiedel AC, Müller CE.
    Arch Pharm (Weinheim); 2017 Apr 31; 350(3-4):. PubMed ID: 28220535
    [Abstract] [Full Text] [Related]

  • 15. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S, Knight A, Krause S, Teceno T, Tresse C, Li S, Cai Z, Gouasmat A, Carroll VM, Barret O, Gottmukkala V, Zhang W, Xiang X, Morley T, Huang Y, Passchier J.
    Mol Imaging Biol; 2020 Aug 31; 22(4):832-841. PubMed ID: 31728839
    [Abstract] [Full Text] [Related]

  • 16. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J, Anderson D, Lynch BA, Castaigne JG, Foerch P, Lebon F.
    Biochem Soc Trans; 2011 Oct 31; 39(5):1341-7. PubMed ID: 21936812
    [Abstract] [Full Text] [Related]

  • 17. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H.
    Epilepsia; 2016 Feb 31; 57(2):201-9. PubMed ID: 26663401
    [Abstract] [Full Text] [Related]

  • 18. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA.
    Epilepsia; 2009 Mar 31; 50(3):422-33. PubMed ID: 18717715
    [Abstract] [Full Text] [Related]

  • 19. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
    Löscher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H.
    CNS Drugs; 2016 Nov 31; 30(11):1055-1077. PubMed ID: 27752944
    [Abstract] [Full Text] [Related]

  • 20. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM, Gillard M, Leclercq K, Hanon E, Lorent G, Dassesse D, Matagne A, Klitgaard H.
    Epilepsia; 2009 Jul 31; 50(7):1729-40. PubMed ID: 19486357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.